252016-79-8

Basic information

• Product Name: (R)-N-[2-chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide
• Synonyms: (R)-N-[2-chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide
• CAS NO: 252016-79-8
• Molecular Weight: 393.789
• Mol File: 252016-79-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (R)-N-[2-chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-[2-chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide(252016-79-8)
• EPA Substance Registry System: (R)-N-[2-chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide(252016-79-8)

Safety Data

• Hazardous Substances Data: 252016-79-8(Hazardous Substances Data)

Upstream product

• 42016-93-3 2-chloro-4-iodoaniline 
• 242139-87-3 (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 2557-78-0 2-fluorothiophenol 

Downstream Products

• 252014-87-2 (R)-N-[2-chloro-4-(2-methylsulphanylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252014-99-6 (R)-N-{2-Chloro-4-[2-(methylsulphinyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252015-02-4 (R)-N-[2-Chloro-4-(2-mesylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3 3-trifluoropropanamide 

Relevant articles and documents

Use of compounds for the elevation of pyruvate dehydrogenase activity

The use of compounds of the formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs: wherein: Ring C is phenyl or a carbon linked heteroaryl ring substituted as defmed within; R1is an ortho substituent as defined within; n is 1 or 2; A—B is a linking group as defined within; R2and R3are as defined within; R4is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.